by Damiano Gentile,
Andrea Sagona, Camilla De Carlo, Bethania Fernandes, Erika Barbieri, Simone Di
Maria Grimaldi, Flavia Jacobs, Giulia Vatteroni, Lorenzo Scardina, Ersilia
Biondi, Valeriano Vinci, Rubina Manuela Trimboli, Daniela Bernardi, Corrado
Tinterri
The Breast: Published: March 27, 2023
Introduction
Residual tumor cellularity
(RTC) and pathologic complete response (pCR) after neo-adjuvant chemotherapy
(NAC) are prognostic factors associated with improved outcomes in breast cancer
(BC). However, the majority of patients achieve partial pathologic response
(pPR) and no clear correlation between RTC patterns and outcomes was described.
Our aims were to define predictive factors for pCR and compare different
outcomes of patients with pCR or pPR and with different RTC patterns.
Materials and
methods
Baseline and
post-NAC demographics, clinicopathological characteristics, post-operative
data, survival and recurrence status were recorded from our institutional
database. A multivariable analysis was performed using a logistic regression
model to identify independent predictors of pCR. Disease-free survival (DFS),
distant disease-free survival (DDFS), and overall survival (OS) analyses were
performed using the Kaplan-Meier method.
Results
Overall, of the 495
patients analyzed, 148 (29.9%) achieved pCR, 347 (70.1%) had pPR, and the
median RTC was 40%. Multivariable analysis identified 3 independent factors
predictive of pCR: tumor stage before NAC (cT1-2 84.5% versus cT3-4
15.5%), BC sub-type (HER2-positive 54.7% versus triple-negative
29.8% versus luminal-like 15.5%), and vascular invasion (absence
98.0% versus presence 2.0%). We found statistically significant
longer DFS, DDFS, and OS in patients with pCR and with RTC <40%; no
difference was observed in terms of OS between RTC <40% and RTC ≥40% groups.
Conclusions
Tumor stage before
NAC, BC sub-type, and vascular invasion are significant and independent factors
associated with pCR. Patients with pCR and with RTC <40% have longer DFS,
DDFS, and OS compared with patients with pPR.